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Introduction
Inorganic materials have attracted the attention of researchers across the world, simply due to their extraordinary properties compared to their organic counterparts. The most commonly adopted ones, including calcium carbonate (CaCO 3 ) nanoparticles, gold nanoparticles and silica nanoparticles (SLNs), have been successfully applied in the biomedical field for more than a decade. [1] [2] [3] Among these inorganic materials, the introduction of SLNs has been considered a milestone, since SLNs have more advantages over other inorganic materials, such as ease of synthesis as well as convenient surface modification. On the other hand, high biocompatibility and biodegradability have made them a suitable carrier for biomedical applications. 4 Their large surface area and pore volume also guarantee high drug-loading capacity for a variety of drugs, ranging from hydrophobic to hydrophilic ones. In all, SLNs are suitable candidates to be developed as versatile carriers for drug delivery and imaging applications. 5 A successful drug delivery system (DDS) for effective cancer therapy requires the capability to bypass the multiple extracellular and intracellular barriers to increase targeted drug accumulation in the tumor tissue, which is beneficial for reducing the unwanted side effects. 6 Two of the greatest challenges for common DDSs are escaping the capture of reticuloendothelial system (RES) and targeting the tumor tissue. 7 It has been demonstrated that SLNs without surface modifications can be recognized by the RES, retarded in the liver and finally excreted out of the body. Many researchers have worked to resolve this dilemma by employing polyethylene glycol (PEG) to encapsulate SLNs. By forming a tunable layer to seal the surface of SLNs, the in vivo interactions between SLNs and RES can be greatly reduced which is beneficial to the in vivo performance of SLNs. 8 However, PEG layer does not have the ability to recognize the abnormal upregulated receptors on the surface of cancer cells in order to guide the DDS to the wanted tumor tissue. The passive targeting of PEG-modified SLNs cannot meet the increasing demands in cancer therapy. As a result, endogenic materials capable of both escaping RES capture as well as targeting tumor tissues are widely recognized as a preferable way to reconcile this dilemma.
Low-density lipoprotein (LDL) is a widespread component responsible for cholesterol transport in plasma. As an endogenic component within the human body, LDL shows high biocompatibility and extremely low cytotoxicity. 9 On the other hand, it has been demonstrated that LDL has high affinity to LDL receptors (LDLR), a specific receptor which has been proved to be upregulated on the surface of many cancer cell lines, including breast cancer, prostate cancer and colorectal cancer. 10 The concept of employing LDL-modified nanoparticles for tumor-targeted drug delivery has been widely adopted. 11 LDL-modified nanoparticles not only exert high biocompatibility and low cytotoxicity, but also have preferable tumor-targeting capabilities. These facts suggest that drug carriers with surface-modified LDL may be used as a suitable system for chemotherapeutic agents to neoplastic cells. 12, 13 We developed LDL-modified SLNs with the aim to construct a DDS that is capable of delivering Adriamycin (Adr) specifically to the tumor site to achieve a better anticancer effect compared with unmodified SLNs and free drugs.
Material and methods

Material
Triton X-100, tetraethyl orthosilicate (TEOS) and N-(2aminoethyl)-3-aminopropyltrimethoxysilane (AEAPS) were obtained from the Sinopharm Chemical Regent Co., Ltd (Shanghai, China). Adriamycin hydrochloride was supplied by Aladdin Bio-chem Technology (Shanghai, China). Plasmaderived LDL was obtained from Intracel (Frederick, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), coumarin 6 (C6) and 1,1-dioctadecyl-3,3,3,3tetramethylindotricarbocyanine iodide (DiR) were purchased from Sigma-Aldrich (St. Louis, USA). All other chemicals and reagents (unless stated otherwise) were from Sinopharm Chemical Reagent Co., Ltd, and of analytical grade.
Cell culture and animal model
Human colorectal cancer cell line HT-29 was purchased from American Type Culture Collection (ATCC, Manassas, USA). The cells were maintained in Dulbecco minimum essential medium (DMEM) (containing 10% volume ratio of endotoxin free fetal bovine serum (FBS), 2 mM glutamine and 100 U/mL streptomycin and penicillin) at 37°C in a humid atmosphere with 5% CO 2 and 95% air.
Male BALB/c nude mice (~18 g) were acquired from Shanghai Laboratory Animal Center, China, and were maintained in a specific pathogen-free (SPF) lab at the homothermal condition of 25 ±2°C with free access to food and water. All procedures were in strict compliance with our institute guidelines for the care and use of laboratory animals and approved by China Medical University Laboratory Animal Welfare and Ethical Committee (No. 20170115). The generation of HT-29 tumor-bearing nude mice model was originated from the previous report. 14 Briefly, 2 × 10 6 HT-29 cells were dispersed in 100 μL of phosphate buffer saline (PBS) and subcutaneously injected into the flank of each mouse.
Preparation of LDL/SLN/Adr
Amine-decorated SLNs (ASLNs) were first synthesized in a water-in-oil microemulsion with minor modification as previously reported. 15 In brief, a water-in-oil microemulsion was prepared by mixing 1.8 mL of Triton X-100, 1.6 mL of n-hexanol and 7.5 mL of cyclohexane. The mixture was gently agitated for 0.5 h to obtain a transparent solution. Afterwards, 180 μL of TEOS together with 60 μL of AEAPS were added under agitation to allow for well dispersion within the microemulsion as precursors for silica formation. One hundred μL of ammonia solution (NH 4 OH) was then added to initiate the polymerization process. The reaction was performed continuously under room temperature for 24 h, followed by the addition of 50 mL of ethanol to precipitate the ASLNs. The precipitate was washed with ethanol and water alternatively several times to remove the surfactant and unreacted reactants from the particles.
The ASLNs were resuspended in 10 mL of water with agitation. Adriamycin dissolved in water (5 mg/mL) was added and co-cultured with ASLNs for 6 h. Afterwards, the drug-loaded ASLNs was isolated under high speed of centrifugation (8,000 × g, 10 min, XPN-100; Beckman Coulter, Brea, USA). The remaining Adr in the supernatant was determined using fluorescence spectrophotometer (FluoroMax-4; HORIBA Scientific, Paris, France). The drug-loaded SLNs were resuspended in aqueous solution, to which LDL (1 mg/mL) was added and co-incubated with gentle agitation at room temperature for 12 h. Finally, the Adr-loaded DDS based on LDL-modified SLNs (LDL/ SLN/Adr) was isolated from the solution using high speed centrifugation.
Drug loading content (DLC) was calculated according to the following formula: DLC (wt%) = (weight of loaded drug/ weight of LDL/SLN/Adr) × 100%
Particle size, distribution and zeta potential measurement
Characterization of nanoparticles concerning their size distributions, polydispersity index (PDI) and zeta potential were assessed at 25°C by dynamic light scattering (DLS) and electrophoretic light scattering (ELS) methods using a Zeta plus zeta potential analyzer (SZ-100; HORIBA Scientific, Paris, France).
In vitro release experiments
The release behavior of Adr from LDL/SLN/Adr was investigated. LDL/SLN/Adr was diluted in PBS (pH 7.4 and 5.0, containing 0.1% Tween 80, w/v) and maintained at 37°C with gentle shaking (100 rpm). At predetermined time intervals, 1 mL of the solution was extracted and an equal volume of fresh medium was supplied. The extracted solution was centrifuged at 8,000 × g for 10 min to remove the nanoparticles and the supernatant was subjected to fluorescence measurement.
Cellular uptake of LDL/SLN/Adr
Fluorescent probe C6 was dissolved in ethanol (0.1 mg/mL) and loaded into nanoparticles along with drug loading. The internalization profile of Adr loaded amine-decorated SLNs (ASLN/Adr) and LDL/SLN/Adr in HT-29 cell line was assessed by monitoring the fluorescence signal of C6. HT-29 cells cultured in confocal dishes (Φ = 15 mm) with 60% confluence were treated with 1 mL of the serum-free medium containing free C6, C6 containing ASLN/Adr or C6 containing LDL/SLN/Adr at the C6 concentration of 350 ng/mL. After 2 h, 4 h and 6 h of incubation, the medium was discarded and cells were rinsed 3 times with PBS to remove the remaining nanoparticles. Afterwards, cells were treated with tyrosine to obtain monodispersed cell suspension. For quantitative determination of the fluorescence intensity of each group, the culture media were discarded, and the cells were harvested and subjected to flow cytometer (FCM) (Attune NxT; Thermo Fisher Scientific, Waltham, USA). The potential LDLR-mediated uptake of LDL/SLN/Adr was confirmed by competitive binding experiments. Then, all the cells were first treated with serum-free medium containing 200 μg/mL of LDL solution for 2 h. Afterwards, free C6, C6 containing ASLN/Adr or C6 containing LDL/SLN/Adr was added to the same medium to achieve the same C6 concentration as mentioned above. After the same procedure, the fluorescence intensity of each group was quantitatively determined by FCM and compared with LDL-untreated groups.
Cytotoxicity activity
To study the cytotoxicity of free nanoparticles and LDL/ SLN/Adr, the HT-29 cells were detached using 0.5% trypsin, harvested, seeded into a 96-well plates, and allowed to grow overnight to reach a confluence of 70-80%. Then cells were incubated with fresh medium containing different samples: free Adr solution, drug-free LDL/SLN, ASLN/Adr, and LDL/SLN/Adr (Adr concentration was set at 0.1, 0.25, 0.5, 1.25, 1.5, 1.75, and 2 μg/mL). After different intervals of incubation, standard MTT assay was applied to evaluate the cell viability of all tested samples as reported previously. 16 
In vivo tumor-targeting of LDL/SLN/Adr
Mice with tumor volumes at about 100 mm 3 were recruited and randomly assigned to perform in vivo experiments. The DiR as a near infrared fluorescent probe was encapsulated into the nanoparticles similar to the C6 loading process. Afterwards, DiR-loaded ASLN/Adr and LDL/SLN/Adr were injected into the HT-29 tumorbearing mice via tail vein at the DiR dosage of 10 μg per mouse. The in vivo real-time biodistribution of different nanoparticles at 2 h, 4 h and 8 h were recorded using in vivo imaging system (MIIS; Molecular Devices, San Jose, USA) with filters set at excitation and emission at 720 nm and 790 nm, respectively. In order to confirm the LDLR-mediated targeting capability of LDL/SLN/Adr, the mice were first intratumorally injected with LDL (5 mg/kg) 1 h prior to the injection of DiR-loaded LDL/SLN/Adr, and then in vivo-imaged as mentioned above. The tissue distribution of nanoparticles at the end of the experiments was acquired by excising the tumor tissues as well as major organs from the sacrificed mice and subjecting them to ex vivo imaging using the same equipment.
In vivo antitumor efficacy
The in vivo antitumor efficacy of LDL/SLN/Adr was further confirmed by employing HT-29 tumor xenograft models. All mice were randomly divided into 4 groups (n = 5): 1. saline (control); 2. free Adr; 3. ASLN/Adr; 4. LDL/SLN/Adr. Protocols regarding administration route and dosing frequency were similar to the previous report with some modifications. 17 In brief, all formulations were administrated via tail vein (5 mg/kg Adr per mouse) once every 2 days 7 times. The body weights and tumor sizes of all treated mice were monitored and recorded before injection. Two days after the last injections, 3 mice from each group were randomly picked and sacrificed. Their tumor tissues were sliced and subjected to hematoxylin-eosin (H&E) staining, and images were taken with a microscope (LSM 510; Zeiss, Oberkochen, Germany).
Results
As shown in Fig. 1A , the ASLNs obtained by water-in-oil microemulsion were nano-sized particles with a diameter of about 92.7 nm. These particles were well-dispersed, with a relatively small polydispersion index (PDI) of 0.264. Compared with the particle size of ASLNs, LDL/SLNs demonstrated a slightly increased size of about 121.3 nm with a decreased PDI of 0.115. It can be seen in Fig. 1B that the originally prepared ASLNs are positively-charged particles with a surface charge of +29.8 mV. However, the surface charge was totally reversed after modification of LDL, with a negative charge of −17.5 mV being observed. According to the fluorescence analysis, the DLC for Adr was 8.6%, which is high enough for both the following in vitro and in vivo experiments.
It can be observed in Fig. 2 that the drug-release speed of Adr was slow in physiological conditions (pH 7.4) with less than 15% of the encapsulated drugs being leaked into the medium after 120 h of incubation. On the contrary, under the acidic condition (pH 5.0), the drug release of Adr was accelerated. The release rate of Adr was more than 3 time the speed of that in pH 7.4, with nearly 60% of the encapsulated drugs being released after 120 h of incubation.
As shown in Fig. 3 , higher C6 fluorescence signals were observed at 2 h post-incubation in the cells of LDL/SLN/Adr group, compared to that of LDL-unmodified ASLN/Adr, as revealed by FCM results. This difference did not disappear but became more serious as incubation continued. It was also calculated from FCM data that the fluorescence intensity of LDL/SLN/Adr was approx. 1.56-fold higher than that of ASLN/Adr after incubation for 6 h. It was also noted that, during the whole incubation time, the intensity of fluorescence signals in free C6-treated cells was much lower than the intensity of these signals in groups treated with DDSs. As displayed in Fig. 4A , when treated by drug-free LDL/ SLNs, no significance was found among all adopted concentrations as more than 90% of the cells survived the dosing concentrations. The following anticancer assay with drug-loaded nanoparticles showed some interesting results. It was clear that all Adr-containing formulations had anticancer effects on HT-29 cells and this effect was dose-related, as higher drug dosing would lead to more serious cell mortality. The cytotoxicity of cells treated with LDL-modified formulations was more severe than the cytotoxicity of the unmodified ones under the same conditions.
In Fig. 5A , it was clear that ASLN/Adr and LDL/SLN/Adr showed significant differences in targeting efficacy after in vivo administration and that the fluorescence intensity of tumor site in LDL/SLN/Adr-treated mice was stronger than that of ASLN/Adr at the same period. The difference in tumor targetability was also verified by using ex vivo imaging of the tumor tissues and main organs of the sacrificed mice (Fig. 5B) . In detail, the fluorescence intensity of the tumor tissues in LDL/SLN/Adr-treated mice was 3.24-fold higher than the fluorescence intensity of ASLN/Adr-treated mice. Moreover, it was interesting to find that the fluorescence intensity of the livers showed an opposite result; it was 1.53-fold higher in ASLN/Adr-treated mice than the fluorescence intensity of LDL/SLN/Adr-treated mice.
As shown in Fig. 6A , although all the formulations can suppress tumor growth to some extent, the anticancer efficacy of LDL/SLN/Adr appeared to be most potent compared with others, since animals treated with LDL/SLN/Adr showed the smallest tumor volumes of 468 ±51 mm 3 . In Fig. 6B , the body weight of mice treated with free Adr steadily decreased. However, no noticeable loss in body weight was observed in LDL/SLN/Adr-treated group. Hematoxylin-eosin staining assay and the representative pictures were displayed in Fig. 6C . It was observed that the cells in negative control group (saline) showed typical pathological characteristics of a tumor, such as large and irregularly shaped nuclei, which were closely packed with one another. Other drug-included formulations showed characteristics of cancer cell remission with tumor coagulative necrosis, intercellular blank and nuclei 
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fragmentation being observed. Compared with the other groups, the LDL/SLN/Adr group showed a massive cancer cell remission with the most promising antitumor ability.
Discussion
The ASLNs were surface-modified with free primary amine groups, which were capable of assembling into multifunctional DDSs with other molecules via either chemical reaction or physical interaction. 18 It has been reported that the water-in-oil microemulsion method can control the size of the particles using the generated water pools in the microemulsion. These pools are composed of a water core and a surfactant shell, which can define the reaction zone. On the other hand, the surfactant shell can also serve as a spacer to prevent the neighboring nanoparticles from aggregation. 19, 20 The LDL was anchored to the surface of ASLNs via electrostatic adsorption. The attachment of LDL resulted in an increase in particle size of LDL/SLNs as compared with unmodified SLNs. The decreased PDI value of LDL/SLNs indicated that surface modification of hydrophilic LDL might further benefit the dispersion of LDL/SLNs, since it has been demonstrated by previous reports that hydrophilic surface modification, such as PEG, can increase the colloidal stability of the recipient. 21, 22 On the other hand, the successful modification of LDL to the surface of SLNs was further proven by zeta potential measurement. The negatively-charged surface, according to the previous report, might be beneficial for the ability of the DDSs to bypass the recognition of many active components within the circulation system, and might ensure safe delivery of the drugs. 23 Due to their large surface area and pore volume, SLNs were capable of loading a variety of drugs, ranging from hydrophobic ones to hydrophilic ones, with a relatively high loading efficiency. This is beneficial for SLNs to act as a co-delivery carrier for the loading of Adr.
One significant drawback of some currently available DDSs is that they are not able to meet the controversial requirements of drug delivery. In the 1 st stage, while DDSs are circulating in the blood, it is beneficial to preserve the encapsulated drugs safely in the circulation system, since the leaked drugs might cause severe side effects to normal tissues and organs. However, upon reaching or entering the cancer tissue, DDSs should be able to accelerate their release rate in a different manner. In order to simulate the drug release profile of LDL/SLN/Adr in physiological and neoplastic conditions, drug release percentages of our system was monitored and recorded under PBS with different pH values. The pH 7.4 was mimicking the physiological condition while pH 5.0 was mimicking the intracellular condition of cancer cells, since all of the cancer cells have a relatively acidic pH conditions when compared with normal cells or blood conditions. The faster drug release of LDL/ SLN/Adr in pH 5.0 than that in pH 7.4 could be explained by the fact that Adr is a weak base and its solubility might be increased in acidic conditions. It is beneficial to increase the drug release of the loaded Adr under acidic conditions. These results were encouraging since they revealed the potential of LDL/SLN/Adr to accelerate its drug release under acidic condition instead of in physiological condition. Since it has been reported that tumor tissue is composed of many highly active cells with high expression of many kinds of enzymes and capable of secreting various constituents, the drug-release speed of LDL/SLN/Adr was expected to be further enhanced as the decomposition of the carrier and competitive dissociation under such conditions will be more serious than that in PBS. This could be beneficial for drug release more intensive in neoplastic tissues than in normal areas to reduce the side effects of chemotherapy and increase the anticancer efficacy of the drugs. It has been demonstrated by many previous articles that LDL anchored toward the surface of the DDS can target LDLR, which is excessively expressed in various cancer cells, including colorectal cancer. 24 In order to verify that our DDS is also capable of specifically targeting LDLRoverexpressed HT-29 cells, C6 was employed as both a fluorescence probe and a hydrophobic drug molecule to mimic the uptake profile of Adr. A quantitative analysis of the uptake behavior of different samples by FCM at different time points was also conducted. Results presented in Fig. 3 suggested that LDL/SLN/Adr can be more effectively internalized by HT-29 cells than its counterpart (ASLN/Adr). During the whole incubation time, the fluorescence signals intensity in free C6-treated cells was all much lower than the fluorescence signals intensity in the DDSs-treated groups. Such result could be explained by the fact that C6 as a drug molecule can be excreted outside the cells via P-glycoprotein, a common transporter associated with multi-drug resistance of cancer cells. 25 However, some evidence has shown that DDSs-based delivery can bypass and overcome such excretion effect to improve the anticancer efficiency of the loaded drugs. In addition, we also performed competitive uptake experiments to further confirm the LDLR-associated uptake of LDL/SLN/Adr. A great decline in fluorescence intensity of LDL/SLN/Adr group was observed at all time intervals after pretreatment of excess LDL, while the fluorescence intensity of ASLN/Adr group still remained at the same level. These results clearly concluded that LDL/SLN/Adr was internalized into cells via LDLR-mediated endocytosis.
In order to further explore and verify the in vitro Adr-delivery efficiency and anticancer efficiency of the well-designed LDL/SLN/Adr, MTT assay was employed to evaluate the cell viability and to demonstrate the results of cytotoxicity. Prior to the MTT assays of drug-loaded formulations, the cytotoxicity of drug-free LDL/SLNs were firstly conducted with nanoparticle concentrations ranging from 5 to 500 µg/mL to seek out whether the carriers we adopted in this study have cytotoxicity effects on HT-29 cells and to what extent it can influence the final results. Our results indicated that the LDL/SLNs we constructed had low cytotoxicity and were biocompatible, which shows a broad range of their potential application in the field of cancer therapy and other biomedical fields. Low-density lipoprotein modification can increase the cellular uptake of LDL/SLNs as proven by cellular uptake experiments, as the cytotoxicity of cells treated with LDL-modified formulations is more severe than the cytotoxicity of the unmodified ones under the same conditions, which was in accordance with cellular uptake assays. Low-density lipoprotein modification on the surface of LDL/SLN/Adr was expected to aid the nanoparticles to bypass the RES and result in their increased accumulation at the tumor site. To verify this conjecture, we employed non-invasive near-infrared (NIR) optical imaging technique as well as NIR fluorescence probe-loaded nanoparticles to monitor the real-time tumor-targeting ability of the DDS. The distribution of DDS at the tumor tissue was reflected by monitoring the NIR fluorescence within the tumor site of HT-29 tumor-bearing nude mice for up to 8 h and is displayed in Fig. 5 . The in vivo images at the tumor site after intravenous injection of DiR loaded nanoparticles at different time points were recorded. These results were consistent with the previous report that positively-charged DDSs can preferably be captured by the liver, while negatively-charged ones can reduce this dilemma. 23 These results indicated that LDL/SLN/Adr had stronger tumor-targeting ability than ASLN/Adr and that it showed preferable accumulation at the tumor tissue. They showed that LDL/SLN/Adr can act as a safe and effective DDS that delivers its payload to the targeted cells and achieves better anticancer effect.
With the aim to find the in vivo antitumor potential of LDL/SLN/Adr in HT-29 xenografted nude mice, LDL/SLN/Adr, ASLN/Adr as well as free Adr were assessed in regard to their ability to suppress tumor growth and influence body weight variation, with saline as a blank control. The observations suggested the enhanced tumorhoming property of LDL/SLN/Adr due to the modification of LDL. Moreover, the time-and formulation-dependent variations in body weight of subjected mice were recorded. Free drugs, especially Adr, were demonstrated to have strong system toxicity, which would result in body weight loss. As shown in Fig. 5B , the body weight of mice treated with free Adr steadily decreased, indicating that the health condition of mice was compromised, either due to tumor burden, side effects of free drugs or the combination of them. However, no noticeable loss in body weight was observed in LDL/SLN/Adr-treated group, suggesting that LDL/SLN/Adr could not only increase the anticancer efficacy of free drugs, but also reduce the safety risks. The H&E staining results also allowed for the same conclusion.
Conclusions
In summary, a tumor-targeting DDS composed of LDL and SLNs loaded with Adr was developed (LDL/SLN/Adr) to take advantage of the tumor-targeting ability of LDL and drug-loading property of SLNs for the safe and effective chemotherapy of colorectal cancer. Our experimental results indicated that nano-sized LDL/SLN/Adr with decent drug loading could preserve the encapsulated drugs under physiological condition, while unloading it in a faster way under acidic neoplastic conditions. On the other hand, LDL/SLN/Adr could increase the uptake ratio of drugs into HT-29 colorectal cancer cells compared with unmodified ASLN/Adr, possibly via the LDLR-mediated endocytosis. More importantly, LDL/SLN/Adr exhibited stronger anticancer activity in vivo with minimized toxic side effects and preferable tumor-suppression potential in HT-29 tumor-bearing nude mice model.
